2003;33(7):1830C1838. [66,67] and PLs [68] have also been previously reported in MS. The pathogenic role of glycosphingolipids and PLs in MS is Regorafenib monohydrate summarized in Table 3. Considerable interest has been stirred by a study employing lipid-array analysis that found antibodies to sulfatide, sphingomyelin, several PLs, oxidized PLs and oxidized sterols in MS cerebrospinal fluid (CSF) [69]. Another fundamental and exciting recent development has been a growing realization of the importance of the potent lipid bioactive breakdown products [70C79] (lyso-sphingolipids), emphasizing the relevance of lipids as mediators of injury to myelin and related CNS injury, as well as antigens. Our own studies of cross-reactivity of the Regorafenib monohydrate myelin marker acetyl-cerebrosides (FMCs) with mycoplasma and other complex lipids (see following section) support a role for lipid antigens in the MS mechanism. Table 3 Pathogenicity of glycosphingolipids and phospholipids in multiple sclerosis. antigens [102]. This strongly suggests that molecular mimicry of PNS myelin gangliosides and microbial glyco-eiptopes on LPS is a mechanism of the autoimmune neuropathy. Since a major difference between the CNS and PNS is the abundance of neolacto-series gangliosides in the PNS, it appears most likely that a molecular mimicry mechanism involving FMCs is not applicable to the demyelinating neuropathy in PNS. Another PNS example is the MillerCFisher syndrome, a variant form of acute inflammatory GBS neuropathy affecting control of eye movement that manifests molecular mimicry of sialylated epitopes of the liposaccharides (LPS) of and gangliosides in the PNS [103]. Thus, molecular mimicry between infectious agents and Regorafenib monohydrate GSLs may function in the production of anti-GSL antibodies and this is a plausible mechanism of GBS, MillerCFisher syndrome [104,105] and multifocal motor neuropathy [106]. In gastric infection, another organ site is implicated for serum anti-GM1 antibody titers are elevated in patients with infection. Coupled with the finding that antigens, this suggests that both of these GI tract-resident bacteria have a common LPS structural feature that resembles GM1 [107]. In addition to and may contribute to the clinical and immunological heterogeneity of GBS and peripheral neuropathies with paraproteinemia by a similar mechanism [108]. For example, human cytomegalovirus infection has been associated with peripheral neuropathies in patients with antibodies against sulfoglucuronyl glycosphingolipids (SGGLs) [109]. The SGGL epitope is present in potential target antigens implicated in the development of IgM paraproteinemia and peripheral neuropathy although the relationship between infectious agent and anti-GSL antibodies has yet to be defined [109]. It would be interesting to test this hypothesis by immunizing animals directly with LPS fractions isolated from these infectious agents in order to establish whether these animals develop anti-GSL antibodies, and whether this could experimentally induce animal neurological disease. Myelin acetyl-cerebrosides: cross-reactivity with microbial lipids The myelin acetyl-cerebrosides resemble acyl-and/or acetyl-carbohydrates of LPS and/or glycolipid found on the external surface of many bacteria [110C117] and thus are candidate lipid antigen mimics targeted by immune responses initially directed at bacterial acyl- or acetyl-conjugated glycosides and subsequently inducing autoimmune inflammation in CNS. Exploring lipid mimicry pathogenesis for induction of MS autoimmunity, we examined CSF IgGs for cross-reactivity between myelin/microbial lipids focusing on acetylcerebrosides, FMCs and other myelin lipids including GalCer and sGalCer; MfGL-II, a glyco-glycero-choline-containing lipid from the human pathogen and [6] that may be relevant to immune triggering Regorafenib monohydrate of myelin-targeted inflammatory demyelination by the mycoplasma glycolipid [6]. We also observed binding of MS CSF to Rabbit Polyclonal to CBLN1 LPS from J5, although not to LPS of other screened bacterial species [6]. As an alternative approach to examine cross-reactivity to lipid antigens employing the functionally enigmatic antibodies found in approximately 95% of MS patients, we studied CSF by comparing other inflammatory neurological disease controls that comprised acute meningitis, meningoencephalitis Regorafenib monohydrate and subacute sclerosing panenecephalitis, other noninflammation neurological diseases, and MS including the main clinical subtypes. Screening for lipid binding in MS and other neurological diseases revealed that the anti-FMC-7 antibody level was significantly higher in primary progressive MS compared with secondary progressive MS; and relapsingCremitting MS in remission compared with a secondary progressive MS cohort [6]. However, the greatest antihydrophobic FMC reactivity was observed in the inflammatory CNS diseases (meningitis, meningoencephalitis and subacute sclerosing panenecephalitis) [6]. In addition, highly elevated antimicrobial (and or J5 infection and demyelination via antibody-mediated recognition. The range of reactivities observed with some of the MS samples,.